17
total announcements
506820.BO · 15 min delayed
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has received an ESG rating of 64 from Crisil ESG Ratings & Analytics Limited, based on publicly available information for fiscal year 2026.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has received a stay order from the Hon'ble High Court of Delhi on the Demand Notice issued by the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013. The stay is until February 10, 2027, subject to the company depositing 15% of the amount mentioned in the Demand Notice with the Registrar General of the Court.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd disclosed its ESG rating of 57 by Crisil ESG Ratings & Analytics Limited, based on publicly available information, without engaging the rating agency.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has scheduled an interaction with an institutional investor on August 26, 2026, as per the details given. The interaction will be held virtually and dates are subject to change.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has announced an interaction with analysts/investors scheduled for August 19, 2026, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has announced the voting results and scrutinizer's report for its 47th Annual General Meeting (AGM) held on August 10, 2026, where all resolutions were passed with the required majority.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd reported a 30% growth in total revenue from operations to INR 6,828 Mn in Q1 FY2026-27, driven by continued momentum across its core therapy areas, including Oncology, Biopharmaceuticals, and Rare Disease.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd announced the outcome of its 47th Annual General Meeting (AGM) held on August 10, 2026. The AGM adopted the financial statements for the year ended March 31, 2026, declared a dividend of Rs. 36/- per equity share, and appointed new auditors and an independent director. The company also provided remote e-Voting facility to members.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has announced its Q1 FY2026-27 financial results, reporting a 30% growth in total revenue from operations to INR 6,828 Mn, driven by continued momentum across its core therapy areas. The company has also received regulatory approvals for several new treatments, including acalabrutinib and trastuzumab deruxtecan.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has received permission from the Central Drugs Standard Control Organization to import and sell Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu) for an additional indication in India.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 to consider and approve the Un-audited Financial Results of the Company for the quarter ended June 30, 2026.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013, amounting to Rs. 148.65 crore, including interest.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has submitted a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013. The company is reviewing the notice and will take appropriate steps in accordance with applicable law.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has received permission from the Central Drugs Standard Control Organization to import and market Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu) for an additional indication in India.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has announced that it will deduct tax at source on the final dividend for the financial year 2025-26, as per the Finance Act 2020. The dividend will be paid after deducting tax at source under section 393 of the Income Tax Act, 2025. Resident shareholders who do not have a PAN or have an invalid PAN will have 20% tax deducted, while those who provide a self-attested copy of PAN and meet other conditions may be exempt from tax. Non-resident shareholders will have 20% tax deducted, unless they provide a tax treaty benefit certificate.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has announced the resignation of its Chief Financial Officer (CFO), Ms. Bhavana Agrawal, effective August 31, 2026, due to her appointment to a regional role within the AstraZeneca Group.